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The nature and expression pattern of the 97 kDa linear
IgA bullous dermatosis antigen (LAD-1) and its role in
epidermolysis bullosa have not been fully elucidated. In
this study, we examined the expression of LAD-1 in the
skin specimens of 70 patients with the various subtypes
of epidermolysis bullosa, including simplex (n J 23),
junctional (n J 15), and dystrophic variants (n J 32).
For immunolabeling, we used two recently developed
monoclonal antibodies to LAD-1 whose epitopes were
ultrastructurally localized in the lamina lucida between
NC16A and carboxyterminal domains of BPAG2, as well
as autoantibodies against LAD-1 from the sera of two
patients with linear IgA dermatosis. Among the 70
patients, only one patient with generalized atrophic
benign epidermolysis bullosa failed to demonstrate LAD-
1 expression. Although other major basement membrane
components, including laminin 5, BPAG1, plectin, a6
and b4 integrins, as well as type IV and type VII collagens
Epidermolysis bullosa (EB) is a group of inherited skindiseases that consists of more than 20 clinical variants. Thecharacteristic feature common to each subtype is markedfragility of the skin, with the formation of blisters inresponse to seemingly minor or insignificant trauma (Fine
et al, 1991). Conventional classification of EB into three major types,
simplex, junctional, and dystrophic, is based on the level of blister
formation within the dermal–epidermal basement membrane zone
(BMZ) upon ultrastructural examination.
Recent studies have revealed the existence of distinct BMZ proteins,
recognized by the circulating autoantibodies in patients with certain
autoimmune bullous diseases. Also, mutations in the corresponding
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were normally expressed, BPAG2/type XVII collagen
was absent from the skin of this patient. Mutation analysis
on COL17A1 using polymerase chain reaction amplifica-
tion, heteroduplex scanning, and direct nucleotide
sequencing revealed that this patient was homozygous
for a novel nonsense mutation G258X in exon 11, and
her parents were heterozygous carriers for this mutation.
This is the first mutation located in the intracellular
domain of BPAG2, and resides 817 bp upstream from
the N-terminal amino acid sequence of LAD-1. These
findings indicate that the absent expression of LAD-1
is observed in a BPAG2-deficient generalized atrophic
benign epidermolysis bullosa patient with mutations in
both alleles of COL17A1, and not in other epidermolysis
bullosa subtypes. These findings also support the notion
that LAD-1 is a degradation product of BPAG2. Key
words: basement membrane/bullous pemphigoid/hemidesmo-
some. J Invest Dermatol 111:887–892, 1998
genes underlie heritable forms of EB in patients in clinically defined
variants. For example, mutations in the gene encoding type VII
collagen, a target antigen of autoimmune disease epidermolysis bullosa
acquisita (Shimizu et al, 1997a), are responsible for dystrophic EB (Uitto
and Christiano, 1994); laminin 5, a target molecule for autoantibodies in
patients with cicatricial pemphigoid (Domloge-Hultsch et al, 1992;
Shimizu et al, 1995), is the gene/protein system altered in some forms
of inherited junctional EB (Uitto et al, 1994); and mutations in BPAG2,
also known as type XVII collagen, recognized by autoantibodies in
patients with bullous pemphigoid (Diaz et al, 1990), are responsible
for EB in a subgroup of patients known as generalized atrophic benign
epidermolysis bullosa (GABEB) (McGrath et al, 1995a; Jonkman et al,
1996; Gatalica et al, 1997; Scheffer et al, 1997).
Linear IgA dermatosis is an autoimmune blistering disease that is
characterized by subepidermal blister formation with marked neutro-
philic inflammation. In this disease, the 97 kDa linear IgA dermatosis
antigen (LAD-1), which has been suggested to be synthesized as a 120
kDa precursor protein by keratinocytes (Marinkovich et al, 1996), is
the major target molecule for IgA class autoantibodies (Zone et al,
1990). The absence of LAD-1 and BPAG2 in GABEB patients was
first reported in three patients by Pas et al (1997), and this was later
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confirmed in 13 patients by Marinkovich et al (1997). Pas et al (1997)
demonstrated that LAD-1 and BPAG2 are both absent in cultured
keratinocytes as well as in the skin of BPAG2-deficient GABEB
patients, but their expression returns to normal after repair of the
COL17A1 mutation by mitotic gene conversion. Subsequent
immunoscreening of 44 patients with junctional forms of EB also
revealed the absence of LAD-1 in some patients with the GABEB
phenotype (Marinkovich et al, 1997). Pas et al (1997) also showed that
a subset of bullous pemphigoid sera and liner IgA dermatosis sera reacts
with LAD-1, but not with BPAG2, thus suggesting that there are
unique epitopes on LAD-1.
We recently developed monoclonal antibodies against LAD-1 (Zone
et al, 1998), and demonstrated by immunoelectron microscopy that
the epitopes of both antibodies localized in the lamina lucida corres-
ponding to a region between the NC16A domain and the carboxy-
terminal segments of BPAG2 (Ishiko et al, in press). In this study, we
immunoscreened 70 patients with different subtypes of EB for the
expression of LAD-1 using these novel monoclonal antibodies, and
elucidated the molecular basis of EB in a patient with absent expression
of this molecule.
MATERIALS AND METHODS
Patients and skin samples Fresh skin samples were obtained from a cohort
of 70 Japanese patients with various subtypes of EB, who were referred to the
Special Clinic for Genetic Counseling on Inherited Skin Diseases of the Keio
University Hospital, Tokyo, Japan. Diagnoses included EB simplex in 23
patients, consisting of four Dowling Meara (Nomura et al, 1996), two Koebner,
13 Weber-Cockayne, and four EB simplex associated with muscular dystrophy
(Pulkkinen et al, 1996); junctional EB in 15 patients, including seven Herlitz
(Shimizu et al, 1997b), seven non-lethal among which three were with typical
GABEB phenotype, and one associated with pyloric atresia (Shimizu et al,
1996a; Takizawa et al, 1997); dystrophic EB in 32 patients, including 20 with
recessive and 12 with dominant inheritance (Shimizu et al, 1996b). Diagnosis
of the EB subtype was based on the clinical, electron microscopic, and
immunohistochemical features.
Case report: patient with GABEB associated with absence of LAD-1
and COL17A1/BPAG2 expression One of the 70 patients with EB
examined in this study is a 63 y old female with the junctional form of EB
presenting with GABEB phenotype. She showed a complete absence of LAD-
1 expression in her skin. She had a history of generalized trauma-induced
blistering since birth. Examination of her skin revealed blisters, erosions, and
areas of thin, cigarette paper-like atrophic depigmented skin at sites of recurrent
blistering, but no milia. Her growth had been normal. There was moderate
improvement in the severity of blistering with advanced age. She exhibited
dystrophic nails and hypoplastic teeth, mild involvement of the mucous
membranes, and nonscarring alopecia (Fig 1a–f). Her eyelashes and eyebrows
were scanty, and pubic and axillary hair were absent. There was no family
history of EB, and her parents were not known to be related.
Antibodies The following antibodies directed against a range of epidermal
BMZ-associated antigens were used in immunofluorescence studies of the skin.
For LAD-1, we used two newly produced monoclonal antibodies, MoAb 97–
1 and MoAb 97–2, that react with LAD-1 but not with BPAG2 by immunoblot.
Details of production and characterization of these monoclonal antibodies have
been reported elsewhere (Zone et al, 1998). Using immunoelectron microscopy,
we recently confirmed that the epitopes for these two monoclonal antibodies
localized to the lamina lucida and recognized a region between the NC16A
domain and carboxy terminal segment of BPAG2 (Ishiko et al, 1998). Two sera
from patients with linear IgA dermatosis that were previously shown by
immunoblot analysis to react with LAD-1 and to bind to the lamina lucida by
immunoelectron microscopy (Ishiko et al, 1996), were also used for detection
of LAD-1. The following monoclonal antibodies were used: for the 180 kDa
bullous pemphigoid antigen (BPAG2), monoclonal antibodies D20, 233, and
1D1 (Nishizawa et al, 1993); for α6 integrin, monoclonal antibody GoH3
(Sonnenberg et al, 1987); for β4 integrin, monoclonal antibody 439–9B (Kennel
et al, 1989, 1990); for HD1/plectin, monoclonal antibody 121 (Hieda et al,
1992); for the 230 kDa bullous pemphigoid antigen (BPAG1), polyclonal
antibody S1193 (Tanaka et al, 1994); for laminin 5, monoclonal antibody
GB3 (Verrando et al, 1991) (Sera Laboratory, Cambridge, U.K.); for uncein,
monoclonal antibody 19-DEJ-1 (Fine et al, 1989, 1990); for type VII collagen,
monoclonal antibody LH7.2 (Leigh et al, 1987) (Chemicon); for type IV
collagen, a commercially available monoclonal antibody (Dakopatts, Denmark).
Immunofluorescence Immunofluorescence was performed as previously
described (Shimizu et al, 1996a). In brief, 6 µm cryostat sections of skin
Figure 1. Clinical and ultrastructural features of the proband with
GABEB. (a–f) Note generalized blistering, scarring alopecia, cigarette paper-
like atrophic and depigmented skin, dystrophic nails, and deteriorated dentition.
(g) Electron microscopy of the edge of the blistered skin demonstrated dermo–
epidermal separation within the lamina lucida between the plasma membrane
of the basal keratinocytes and the lamina densa. (h) The majority of the
hemidesmosomes were hypoplastic with thin attachment plaques and the
absence of a subbasal dense plate. The shape and number of the anchoring
fibrils appeared normal.
specimens obtained from the area on and around an existing blister or from a
blister that was induced by applying friction, were embedded in OCT and
stored frozen at –80°C. They were subsequently incubated at 37°C for 60 min
with the primary antibody. After washing with phosphate-buffered saline, the
sections were incubated with fluorescein isothiocyanate-conjugated secondary
antibodies (Dako, Denmark). After a further washing, the sections were mounted
and viewed under a standard Olympus microscope equipped for epifluorescence.
Normal mouse, rat, rabbit, or human serum was used as negative controls.
Electron microscopy Transmission electron microscopy was performed as
previously described (Shimizu et al, 1994). In brief, skin specimens from the
patient with GABEB, who showed no detectable expression of LAD-1, were
fixed with 2% glutaraldehyde and osmium, and embedded in epoxy resin.
Semi-thin sections were stained with toluidine blue. Ultrathin sections were
cut from the edge of the blister in the same block of tissue, stained with uranyl
acetate and lead citrate, and examined with a transmission electron microscope.
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Identification and verification of mutations in the COL17A1
gene Mutation analysis of the COL17A1 gene was conducted in the family
of the proband with GABEB with absent expression of LAD-1. Genomic DNA
was extracted from the peripheral blood of the proband and her parents.
The exons and flanking intronic sequences of COL17A1/BPAG2 (GenBank
accession no. U76564-U76604) were amplified by polymerase chain reaction
(PCR) using genomic DNA as template. The oligonucleotide primers used for
the amplification of COL17A1 exons were previously reported (Gatalica et al,
1997). Specifically, the following primers were used for amplification of exon
11: the sense primer, 59-CATTTCTTCTGGTGCTTCTG-39; the anti-sense
primer, 59-CAGTATGCATGGAAGAAAGG-39. PCR products were then
screened for potential nucleotide substitutions by heteroduplex analysis using
conformation-sensitive gel electrophoresis (Ganguly et al, 1993). DNA sequen-
cing was carried out with an automatic sequencer (Genetic analyzer 310 A;
Perkin Elmer ABI, Foster City, CA).
The mutation identified in the COL17A1 gene was verified from the proband
with GABEB and her parents by restriction endonuclease digestion. Specifically,
the mutation G258X in exon 11 (see Results) created a new restriction enzyme
site for the endonuclease DdeI.
RESULTS
Expression of LAD-1 and other BMZ epitopes in patients with
EB Only one of the 70 patients with GABEB showed entirely
negative expression of either LAD-1 or BPAG2. The remaining 69
patients showed positive expression for LAD-1 and BPAG2, whereas the
expression of the following cutaneous BMZ molecules was abnormal: in
four cases of EB with muscular dystrophy, staining with monoclonal
antibody 121 recognizing plectin/HD1 was negative or markedly
reduced (Pulkkinen et al, 1996). The seven cases of lethal-Herlitz
junctional EB were negative for staining with monoclonal antibody
GB3 recognizing laminin 5 (Shimizu et al, 1994). Staining with GB3
was also reduced in six cases of non-lethal junctional EB, including
two cases with the GABEB phenotype. The labeling for LH7.2, which
recognizes type VII collagen, was negative in six patients, and markedly
reduced in 14 patients with recessive dystrophic EB (Shimizu et al,
1996b). Skin from an EB patient with the pyloric atresia was negative
for the α6 integrin, whereas expression of the β4 integrin was markedly
reduced (Shimizu et al, 1996a).
Immunohistochemistry of the skin in the proband with
GABEB Immunolabeling for two monoclonal antibodies, MoAb
97–1 and MoAb 97–2 (Fig 2A, C), as well as the sera from two
patients with linear IgA dermatosis (Fig 2E), proved to be negative in
the skin of the proband with GABEB. All three monoclonal antibodies
against BPAG2 used in the study also showed negative labeling in the
skin of this particular patient (Fig 2G). The skin of this patient
expressed all other BMZ components, including laminin 5 (Fig 2H),
type VII collagen (Fig 2I), and β4 integrin (Fig 2J), as well as α6
integrin, BPAG1, HD1/plectin, and type IV collagen (data not shown),
with findings being comparable with those in normal controls. The
use of monoclonal antibody 19-DEJ-1 revealed negative staining for
uncein in the skin of all 15 cases of junctional EB (Fine et al, 1990).
Blister formation at the lamina lucida with hypoplastic
hemidesmosomes Electron microscopy of the edge of the blistered
skin taken from the proband with negative LAD-1 and BPAG2
expression demonstrated dermo–epidermal separation within the lamina
lucida between the plasma membrane of the basal keratinocytes and
the lamina densa (Fig 1g). The majority of the hemidesmosomes were
hypoplastic with thin attachment plaques and the absence of a subbasal
dense plate (Fig 1h). The shape and number of the anchoring fibrils
appeared normal.
Identification and verification of nonsense mutation G258X in
COL17A1 To detect any potential mutations in the proband’s family,
we performed heteroduplex analysis by conformation-sensitive gel
electrophoresis, followed by direct automated sequencing of the PCR
products spanning the entire coding region of the COL17A1 gene. As
shown in Fig 3(A), heteroduplex analysis using PCR products that
span exon 11 and flanking intronic sequences of the father and the
mother demonstrated heteroduplex bands, whereas the proband and
an unrelated control showed a homoduplex band only. When the
Figure 2. Immunofluorescence of the skin from the proband
demonstrated the lack of 97 kDa linear IgA dermatosis antigen (LAD-
1). Indirect immunofluorescence of the skin specimen from the proband (A,
C, E, G, H, I, J) and normal control (B, D, F). Labeling with monoclonal
antibodies MoAb 97–1 (A) and MoAb 97–2 (C), as well as with the serum
from a LAD patient (E), was negative in the skin of proband with GABEB,
whereas normal skin from an unrelated control individual showed positive
labeling at the BMZ by these antibodies (B, D, F). Indirect immunofluorescence
of the skin of the proband revealed completely negative expression of BPAG2
(G; detected by monoclonal antibody D20), whereas the expression of other
BMZ molecules, including laminin 5 (H; detected by monoclonal antibody
GB3), type VII collagen (I; detected by monoclonal antibody LH7.2), and β4
integrin (J; detected by monoclonal antibody 439–9B), was clearly positive,
being comparable with those in normal controls.
proband’s DNA was mixed with control DNA, however, a slower
migrating band was noted, suggesting the presence of a homozygous
genetic alteration in exon 11 of the proband’s COL17A1. Direct
sequencing of the PCR products showed that the father and the
mother were heterozygous, and the proband was homozygous for a
G-to-T transversion in codon 258 of the COL17A1 gene. This
mutation substitutes glycine (GGA) by a premature termination codon
(TGA), and is designated G258X (Fig 3B). The G258X mutation
created a new restriction enzyme site for the endonuclease DdeI that
was used for verification of this mutation (Fig 3C). In the case of the
control DNA (lane C), the 218 bp fragment was digested to fragments
of 123 bp, 81 bp, and 14 bp. The G-to-T transversion (G258X)
created a new enzyme site in the 123 bp fragment, which was further
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Figure 3. Identification and verification of the nonsense mutation G258X in the COL17A1 gene. (A) Top, family pedigree; proband with GABEB (1);
the father (F) and the mother (M) were clinically unaffected; bottom, heteroduplex analysis of the PCR product spanning exon 11 of the COL17A1 gene. When
compared with the control (lane C), slower migrating bands (arrow) were observed with the PCR products from the father (lane F) and the mother (lane M). The
proband’s PCR products (lane 1) showed a homoduplex band only; however, when control DNA and the proband’s DNA were mixed, a heteroduplex band (lane
1 1 C) similar to that noted in the parents was seen. (B) Direct nucleotide sequencing of the exon 11 in the father and the mother (data not shown) revealed a
heterozygous G-to-T transversion in codon 258 (G258X mutation) (arrowhead). The proband (lower panel) was homozygous for this mutation. (C) The presence
of this mutation was verified by restriction enzyme digestion. This mutation created a new recognition site for DdeI restriction enzyme. In the case of the normal
allele (lane C), the 218 bp fragment was digested to fragments of 123 bp, 81 bp, and 14 bp. Digestion of the proband’s (lane 1) DNA revealed that the 123 bp
band was further digested to 74 bp and 49 bp fragments, indicating homozygosity for this mutation. The father’s (lane F) and the mother’s (lane M) DNA digests
showed the presence of 123 bp, 81 bp, 74 bp, 49 bp, and 14 bp bands, indicating that they were heterozygous for this mutation.
digested into fragments of 74 bp and 49 bp. In the proband’s DNA,
both alleles of 123 bp fragments were digested, and the digestion of
the 218 bp PCR product resulted in fragments of 81 bp, 74 bp, 49 bp,
and 14 bp. In PCR products from the father (lane F) and the mother
(lane M), only the mutated allele of 123 bp was sensitive to enzyme
digestion that yielded five bands: 123 bp, 81 bp, 74 bp, 49 bp, and
14 bp. These results confirmed that the parents were heterozygous,
whereas the proband was homozygous, for this G258X mutation.
DISCUSSION
Among the 70 patients with various subtypes of EB evaluated in this
study, only one patient, a 63 y old female with non-lethal junctional
EB, showed the absence of LAD-1 and COL17A1/BPAG2 expression.
The clinical phenotype of this patient, including typical alopecia,
atrophic skin, and generalized blistering, corresponds to that of GABEB.
While there were three cases with clinical features of GABEB among
the patients, the lack of LAD-1 or BPAG2 expression was not detected
in the other two cases. Instead, they showed reduced expression of
laminin 5, and mutations in the LAMB3 gene have been found in one
of these cases (unpublished data). Consistent with these observations
is the fact that mutations in laminin 5 genes have been demonstrated
in some patients with GABEB (McGrath et al, 1995b, 1996c). Absent
expression of LAD-1 was previously reported in BPAG2-deficient
GABEB patients (Marinkovich et al, 1997; Pas et al, 1997), and our
data further support the notion that the premature termination codon
mutations in both alleles of the COL17A1 lead to absent expression
of BPAG2, as well as LAD-1, in GABEB patients. Collectively, these
findings attest to the heterogeneity of the molecular basis of EB, which
now involves specific mutations in 10 different genes of the cutaneous
BMZ (Uitto et al, 1997).
Using post-embedding immunoelectron microscopy, we have previ-
ously demonstrated that COL17A1/BPAG2 is a transmembrane molec-
ule in the hemidesmosome (Ishiko et al, 1993), its carboxy terminus
extending into the upper lamina densa (Masunaga et al, 1997). Thus,
BPAG2 may directly connect the intracytoplasmic hemidesmosomal
attachment plaque to the lamina densa. We have also shown by
immunoelectron microscopy that the target epitope of autoantibodies
in patients with linear IgA dermatosis is located within the lamina
lucida (Ishiko et al, 1996), and the LAD-1 epitopes recognized by
monoclonal antibodies MoAb 97–1 and MoAb 97–2 localized to the
lamina lucida corresponding to the region between the NC16A domain
(plasma membrane) and the carboxy terminal segment (upper lamina
densa) of BPAG2 (Ishiko et al, 1998). Thus, all these data are consistant
with colocalization of the extracellular domain of BPAG2 and LAD-
1. Our recent studies revealed that the amino acid sequence of purified
LAD-1 is identical to a portion of the extracellular domain of BPAG2
(Zone et al, 1998). This finding, together with previous data by others
(Marinkovich et al, 1997; Pas et al, 1997), suggesting a close relationship
between BPAG2 and LAD-1, raises the possibility that LAD-1 represents
cleaved fragments of BPAG2 or is an alternative spliced product of the
same gene, BPAG2/COL17A1. It is not clear why antibodies to LAD-
1 do not react with BPAG2 on immunoblot, whereas they react with
LAD-1 and the 120 kDa protein (Zone et al, 1990; Dmochowski et al,
1993; Marinkovich et al, 1996; Pas et al, 1997). The latter proteins
may have unique epitopes that are not present in intact BPAG2 (Pas
et al, 1997).
The majority of mutations in patients with GABEB reside in the
COL17A1 gene (McGrath et al, 1995a, 1996a, b; Chavanas et al, 1997;
Darling et al, 1997; Gatalica et al, 1997; Jonkman et al, 1997; Scheffer
et al, 1997; Schumann et al, 1997; Pulkkinen and Uitto, 1998). The
proband of this study, with absent expression of LAD-1 and BPAG2,
was shown to be homozygous for a novel nonsense mutation, G258X.
This mutation, which is located in exon 11, is predicted to result in
synthesis of markedly truncated polypeptides of BPAG2, as well as in
the reduced mRNA abundance due to nonsense-mediated mRNA
decay (Cui et al, 1995), resulting in absent expression of BPAG2 and
LAD-1.
Interestingly, previously reported mutations in the COL17A1 gene
reside at the extracellular domain of BPAG2 (McGrath et al, 1995a,
1996a, b; Chavanas et al, 1997; Darling et al, 1997; Gatalica et al, 1997;
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Jonkman et al, 1997; Scheffer et al, 1997; Schumann et al, 1997). The
G258X mutation found in our patient is the first mutation located in
the intracellular part of BPAG2, thus providing additional clues to the
nature of LAD-1. Pas et al (1997) showed that the expression of
LAD-1 is absent in BPAG2-deficient GABEB patients. Thus they
hypothesized that BPAG2 and LAD-1 are closely related. We recently
demonstrated that the amino acid sequence of purified LAD-1 is
identical to the extracellular portion of BPAG2, and the N-terminal
amino end of LAD-1 is located 11 amino acids downstream from the
NC16A domain at nucleotide position 1696 in exon 18 (Zone et al,
1998). There are several explanations for the close relationship between
BPAG2 and LAD-1. One is that LAD-1 is a cleavage product of
BPAG2 that exists in vivo or that occurs as a result of proteolytic
digestion in vitro. In the latter case, LAD-1 has no function in vivo
distinct from BPAG2. Alternatively, LAD-1 could represent alternative
splice variants of the same COL17A1 gene and in such a case could
serve a structural role in the BMZ. The G258X mutation is located
at the nucleotide position 877–879 in exon 11. If LAD-1 is a splice
variant of COL17A1, then nucleotide segment 877–879 must be
included in the LAD-1 transcript, otherwise we would have had
detected normal LAD-1 expression in the skin of our patient. Because
the N-terminal amino acid sequence of LAD-1 was located at nucleotide
position 1696 in exon 18 (Zone et al, 1998), the presence of amino
acid 258, encoded by nucleotides 877–879, is unlikely to be seen in
LAD-1 molecules, because either 277 amino acid residues in the 97
kDa molecule are absent, or splicing out of exons 12–17 encoding
amino acid 279–488 is unlikely to have occurred. Furthermore, if
LAD-1 is a splice variant of BPAG2, the mutations in all other patients
with absent expression of LAD-1 and BPAG2 have to reside in
COL17A1 exons that are expressed in both proteins. Therefore, our
data support the hypothesis that LAD-1 is a degradation product, rather
than a splice variant of BPAG2. Alternatively, LAD-1 molecule could
be a different gene product that colocalizes with BPAG2, and the
absence of BPAG2 might lead secondarily to absent expression of
LAD-1. This possibility is very unlikely considering the high degree
of sequence homology between LAD-1 and the extracellular domain
of BPAG2 (Zone et al, 1998).
In summary, we have demonstrated that absent expression of LAD-
1 in the skin of patients with EB could be observed only in BPAG2-
deficient GABEB phenotype, and not in BPAG2-positive GABEB or
other EB subtypes. The novel homozygous G258X mutation of
COL17A1 is the first mutation residing in the intracellular part of
BPAG2. The results support the hypothesis that LAD-1 is a degradation
product of BPAG2, rather than a splice variant.
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